The U.S. Centers for Disease Control and Prevention (CDC) says the use of a gonorrHE vaccine cannot be given during the CTCID vaccination campaign.
The agency said that while the vaccine can be administered to people who are in the United States at least 1 month after vaccination, the vaccine cannot protect against the STIs that are most common in people with gonorrhei.
“This vaccine is not appropriate for use during the vaccine campaign because of the potential for vaccine-associated adverse events,” the CDC said in a statement.
“Gonorrheas vaccine cannot, under any circumstances, be given prior to the onset of symptoms in patients with gonorrhoea or those with a history of previous vaccine-induced infections.”
The CDC says that the vaccine is the only vaccine currently available that is approved for use in humans and has not been found to be safe for use outside the United Kingdom.
However, the U.K. government is not yet allowing the vaccine to be used, saying it is still working to get approval from the European Medicines Agency (EMA) to do so.
It is also unclear when, if ever, the CDC will issue an update on the use and safety of the vaccine.
The vaccine has been available for more than a year, but the agency said last month that it had yet to receive data on its effectiveness in preventing infections.
A spokesman for the EMA told The Verge that there is no current data available that would allow the agency to recommend that patients be vaccinated, but that it would be “important to get more information on the vaccine’s effectiveness.”
“We continue to monitor the vaccine and will respond appropriately when we do.”
This story has been updated to include information from the CDC and the EEMA.